Vesatolimod
TLR7 agonist/antiviral / Toll-like receptor 7 (TLR7) agonist (EC50 = 290 nM in a HEK293 cell line reporter assay; IFNα MEC 3 nM, 100 fold selectivity over TNFα activation).1 Displays significant antiviral activity via immune activation against HIV2,3, Hepatitis B4,5, Norovirus6, and enterovirus7.
Biochemicals & reagents
1228585-88-3
GS-9620
Roethle et al. (2013), Identification and Optimization of Toll-like Receptor 7 (TLR7) Agonists for the Oral treatment of Viral Hepatitis; Med. Chem. 56 7324 Martinsen et al. (2020), The Use of Toll-like Receptor Agonists in HIV-1 Cure Strategies; Immunol. 11 1112 Riddler et al. (2021), Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1; Infect. Dis. 72 e815 Agarwal et al. (2018), Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment;Viral Hepat. 25 1331 Niu et al. (2018), Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV vias a type I interferon-dependent mechanism; Hepatol. 68 922 Tuipulotu et al. (2018), TLR7 Agonists Display Potent Antiviral Effects against Norovirus Infection via Innate Stimulation; Antimicrob. Agents Chemother., 62 e02417 Zhang et al. (2018), GS-9620 inhibits enterovirus 71 replication mainly through the NF-kappaB and PI3K-AKT signaling pathways; Antiviral Res., 153 39
-20°C
TARGET: TLR (Toll-like receptor) -- PATHWAY: TLR signaling -- RESEARCH AREA: Immunology -- DISEASE AREA: Infectious disease; Ischemia